Fidelity Wise Origin Bitcoin Fund amends trust agreement to allow in-kind share transactions
On Monday, UBS analyst Danielle Antalffy updated the price target on Stryker shares, increasing it to $421.00 from the previous $405.00, while maintaining a Neutral rating on the stock. The medical technology giant, currently valued at $143.66 billion, is trading near its 52-week high of $406.19. According to InvestingPro analysis, the stock appears overvalued at current levels, trading at a P/E ratio of 50.13. The adjustment follows Stryker’s recent performance, which included sales and earnings per share (EPS) that surpassed expectations. Additionally, the company has provided guidance that exceeds consensus on its organic sales growth for 2025, now expecting an increase of 8.5% to 9.5% year over year, compared to the earlier forecast of 8% to 9%.
The company’s management acknowledged that it is in the early stages of launching new products, including Mako Spine in the second half of 2025 and Mako Shoulder in the first quarter of 2026. Existing products such as Mako, LifePak, Pangea, and Artix are also gaining traction, bolstering Stryker’s position for sustained sales growth. This product momentum has contributed to impressive revenue growth of 10.76% over the last twelve months, with InvestingPro data showing strong financial health metrics and a "GREAT" overall score of 3.0. The analyst noted that procedure volumes are healthy, largely consisting of non-elective surgeries, and the pricing environment is improving. Capital expenditures are also robust, indicating a continued investment in growth.
Despite these positive indicators, UBS has reiterated its Neutral rating for Stryker stock. The firm expressed the need for greater conviction in the company’s ability to drive margin upside, especially given the current uncertainties in the market. The adjusted EPS guidance to $13.20 - $13.45, without the impact of tariffs, suggests a strong outlook for the company’s financial performance.
Stryker’s focus on innovation and the introduction of new products are expected to play a significant role in its future growth. The company’s solid foundation in the MedTech industry and its reputation for quality growth stocks are highlighted by UBS as key considerations. Adding to its investment appeal, InvestingPro reveals that Stryker has maintained dividend payments for 35 consecutive years, demonstrating remarkable financial stability. However, the premium at which the shares are currently trading is a factor in the decision to maintain a Neutral stance on the stock, with analyst price targets ranging from $306 to $465.
In other recent news, Stryker Corporation (NYSE:SYK) reported impressive financial results for the first quarter of 2025. The company achieved an adjusted earnings per share (EPS) of $2.84, surpassing analyst forecasts of $2.71, and reported revenues of $5.9 billion, exceeding the anticipated $5.68 billion. Stryker’s organic revenue growth reached 10.1%, driven by strong performances in its MedSurg and Orthopedics divisions. Despite these positive results, Evercore ISI lowered its price target for Stryker from $400 to $390, while maintaining an Outperform rating. The firm cited the company’s robust revenue and margin performance but noted potential headwinds from tariffs and foreign exchange impacts.
Stryker also announced an update to its fiscal year 2025 guidance, raising its organic growth forecast to a range of 8.5% to 9.5%, though it lowered its EPS guidance to a range of $13.20 to $13.45. This adjustment accounts for anticipated tariff impacts and other expenses. The company completed the acquisition of Inari Medical (TASE:BLWV) and the sale of its U.S. Spinal Implants business, reflecting its strategic focus on core areas. Stryker’s leadership emphasized the strength of its product offerings, including the Mako robotic system, which reached record installation levels.
Overall, Stryker’s recent developments highlight its strong market position and operational execution, with ongoing challenges related to tariffs and currency fluctuations. The company’s performance was positively received by analysts, despite the stock’s slight dip in after-hours trading following the earnings report.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.